These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1169 related articles for article (PubMed ID: 19146897)

  • 1. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
    Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
    Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
    Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
    Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of O-specific polysaccharide responses in patients following infection with
    Kaisar MH; Kelly M; Kamruzzaman M; Bhuiyan TR; Chowdhury F; Khan AI; LaRocque RC; Calderwood SB; Harris JB; Charles RC; Čížová A; Mečárová J; Korcová J; Bystrický S; Kováč P; Xu P; Qadri F; Ryan ET
    mSphere; 2023 Oct; 8(5):e0025523. PubMed ID: 37646517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
    Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
    PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine.
    Jertborn M; Svennerholm AM; Holmgren J
    Vaccine; 1996 Oct; 14(15):1459-65. PubMed ID: 8994322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Murine antibody responses following systemic or mucosal immunization with viable or inactivated Vibrio cholerae.
    Nygren E; Holmgren J; Attridge SR
    Vaccine; 2008 Dec; 26(52):6784-90. PubMed ID: 18951939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.
    Kamruzzaman M; Kelly M; Charles RC; Harris JB; Calderwood SB; Akter A; Biswas R; Kaisar MH; Bhuiyan TR; Ivers LC; Ternier R; Jerome JG; Pfister HB; Lu X; Soliman SE; Ruttens B; Saksena R; Mečárová J; Čížová A; Qadri F; Bystrický S; Kováč P; Xu P; Ryan ET
    mSphere; 2021 Aug; 6(4):e0011421. PubMed ID: 34232076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of systemic, mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell cholera vaccine in Bangladesh.
    Akter A; Dash P; Aktar A; Jahan SR; Afrin S; Basher SR; Hakim A; Lisa AK; Chowdhury F; Khan AI; Xu P; Charles RC; Kelly M; Kováč P; Harris JB; Bhuiyan TR; Calderwood SB; Ryan ET; Qadri F
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007634. PubMed ID: 31369553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.
    Charles RC; Hilaire IJ; Mayo-Smith LM; Teng JE; Jerome JG; Franke MF; Saha A; Yu Y; Kováč P; Calderwood SB; Ryan ET; LaRocque RC; Almazor CP; Qadri F; Ivers LC; Harris JB
    PLoS Negl Trop Dis; 2014 May; 8(5):e2828. PubMed ID: 24786645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ T-cell responses to an oral inactivated cholera vaccine in young children in a cholera endemic country and the enhancing effect of zinc supplementation.
    Ahmed T; Arifuzzaman M; Lebens M; Qadri F; Lundgren A
    Vaccine; 2009 Dec; 28(2):422-9. PubMed ID: 19837094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential immunogenicity of Vibrio cholerae O139 variants expressing different combinations of naturally occurring and atypical forms of the serogroup polysaccharide.
    Attridge SR; Wallerström G; Li BL; Morona R; Holmgren J
    Vaccine; 2009 Feb; 27(7):1055-61. PubMed ID: 19100303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.
    Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM
    Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.
    Anh DD; Canh DG; Lopez AL; Thiem VD; Long PT; Son NH; Deen J; von Seidlein L; Carbis R; Han SH; Shin SH; Attridge S; Holmgren J; Clemens J
    Vaccine; 2007 Jan; 25(6):1149-55. PubMed ID: 17055622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial.
    Kanungo S; Paisley A; Lopez AL; Bhattacharya M; Manna B; Kim DR; Han SH; Attridge S; Carbis R; Rao R; Holmgren J; Clemens JD; Sur D
    Vaccine; 2009 Nov; 27(49):6887-93. PubMed ID: 19761838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003.
    Kabir S
    Vaccine; 2007 Feb; 25(8):1353-4. PubMed ID: 17049687
    [No Abstract]   [Full Text] [Related]  

  • 20. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding.
    Ahmed T; Svennerholm AM; Al Tarique A; Sultana GN; Qadri F
    Vaccine; 2009 Feb; 27(9):1433-9. PubMed ID: 19146904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.